Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Sep 01, 16:00
Kezar Life Sciences Research and Development Expense (Annual) : 33.76M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 33.76M |
| December 31, 2024 | 65.74M |
| December 31, 2023 | 85.70M |
| December 31, 2022 | 51.09M |
| December 31, 2021 | 38.94M |
| Date | Value |
|---|---|
| December 31, 2020 | 31.04M |
| December 31, 2019 | 28.00M |
| December 31, 2018 | 18.14M |
| December 31, 2017 | 6.469M |
| December 31, 2016 | 7.373M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.976M |
| Summit Therapeutics, Inc. | 537.67M |
| Protara Therapeutics, Inc. | 42.49M |
| Clene, Inc. | 12.66M |